News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

SynCo Bio Partners B.V. Enters the Japanese Market as it Signs its First Agreement With a Japanese Pharmaceutical Company


9/1/2009 11:41:43 AM

AMSTERDAM, September 1 /PRNewswire/ -- SynCo Bio Partners B.V., the expert in long term GMP contract manufacturing of biopharmaceuticals announced today that it has expanded its business into a new geographical market, with the signing of a contract to manufacture a live biotherapeutic for an emerging Japanese pharmaceutical company.

The undisclosed company's product is an innovative live biotherapeutic based anticancer drug. The project will first involve a consultancy phase, during which SynCo will assist the client with in-house process development. The developed process will then be transferred to SynCo's Amsterdam facility and scaled-up, prior to GMP manufacture for Phase I clinical trials, including fermentation, formulation and aseptic filling.

"We are extremely pleased to be working with our first Japanese partner," commented SynCo's CEO, Mr. Pierre Warffemius, "this is an exciting project for a leading Japanese business and I look forward to the successful completion of GMP manufacture, in the field of live biotherapeutics. This contract represents SynCo's entry into the growing Japanese biotherapeutics market and is reflective of our continuing success in a very competitive GMP contract manufacturing market."

SynCo is a specialist in the development of manufacturing processes and GMP production of live biotherapeutics and provides a one-stop-shop for the production of both bulk drug substance and final lyophilized product. This project is one of a rapidly growing number SynCo is involved with in this field.

For more information, please visit http://www.syncobiopartners.com

About SynCo Bio Partners B.V.

SynCo Bio Partners is a GMP-licensed bulk drug substance and final product CMO with clinical and commercial production experience with mammalian and microbial systems. This experience has been acquired by developing new production processes for a number of international clients and producing a wide variety of different vaccines, live bacterial products and recombinant proteins in our state-of-the-art, GMP-licensed facilities since inception in 2000.

Focused solely on biopharmaceuticals, SynCo Bio Partners acts as a strategic, long-term partner delivering product on time to the highest quality standards. SynCo 's team are committed to exceeding customer expectations taking a truly collaborative approach to manufacturing.

http://www.syncobiopartners.com

SOURCE SynCo Bio Partners B.V.

CONTACT: De Facto Communications, Hilary Latham, +44-207-861-3027,
h.latham@defacto.com; SynCo Bio Partners B.V., Joanne McCudden,
+31-6-5534-8074, J.mccudden@syncobiopartners.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES